LA JOLLA, CA, Feb. 04, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the ...

LA JOLLA, CA, July 31, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell ...

GRI Bio, Inc., a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, announced that the European Patent Office has ...

Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival LA JOLLA, CA, July 31, 2025 ...

GRI Bio ( (GRI)) has issued an announcement. On May 14, 2026, GRI Bio reported first-quarter 2026 results and new Phase 2a data showing its IPF candidate GRI-0621 improved key clinical symptoms and ...

LA JOLLA, CA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T ...

LA JOLLA, CA, May 21, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (GRI) (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell ...

The MarketWatch News Department was not involved in the creation of this content. Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA ...

Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year end 2023; Interim data expected H1 2024 Currently available treatments for IPF are limited ...

"In 2025, we prioritized disciplined clinical execution and balance sheet strength, delivering compelling clinical data from our lead IPF program which underscores the therapeutic differentiation of ...